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INTRODUCTION
Recording medical information seems to have started
just after development of writing around 3100BC1,2,3,4. These
ancient records were purely descriptive. Although the oldest
report of an experiment in humans has taken place around
600BC according to the Old Testament and some key concepts
like placebo were known since XIX Century5, the first clinical
trial as we currently conceive it, was published in 19486. The
main feature of this modern approach is the respect to the
experimentation subject, a need widely obviated by World
War II7.
Getting the most out of a medical scientific report is
not a trivial task. A number of skills are required from the
reader. Acquisition and development of those skills should
start during undergraduate years and continue through one’s
professional life since methods have evolved closely as fast
as Medicine itself.
Massive production of medical literature imposes a
first challenge: selecting what is relevant or useless for a given
reader has no rule-of-thumb. Also, quality can vary widely
between reviews and within the same review. Furthermore,
the mainstay of editors credibility, peer review, has been
reported not to assure quality8,9.
Quality and Bias
The very core of medical practice is decision making.
What tests to order, building a list of differential diagnoses,
figuring out the next question to ask, selecting  the most
appropriate therapy, which patient to care for with the highest
priority are just some among the most remarkable. Real life
situations situations are much different from the didactically
organized theory of textbooks. Medical research articles are
born in real daily practice. We read papers to make better
decisions in the clinical setting, probably. And we should
write papers in order to spread knowledge we produce.
The relevance of a research report is a function of
how it influences clinical practice. Of course, this is a highly
subjective definition in a general sense but certainly will make
sense every time one uses or consider using a conclusion
drawn from a research.
The randomized clinical trial (RCT), although seldom
feasible in surgical investigation, is currently the gold standard
in medical research when judging for quality. The reason is
that RCTs are believed to provide means to control bias from
several known sources, and perhaps some we are not aware
of. Thus, the less undesired tendencies the more quality; the
more of such tendencies the less quality.
Evidence-based Medicine
Although we can not assess quality or bias by the
numbers, we can create a hierarchy based on the research methods
that will most likely produce better or worse quality conclusions.
This is the core of the Evidence-based Medicine (EBM).
There are many of such hierarchies. They vary among
institutions10 and, extremely important, if research regards
treatment, prevention, diagnosis, prognosis or harm11. The
choice of classification criteria is up to the reader and the
institutions. Table 1 illustrates one possible hierarchy
applicable to therapy research.
Table 1 – Example of a hierarchy of quality of different study designs.
Level Type of study
1 RCT; double-blind; placebo controlled higher quality less bias
2 other kinds or RCT
3 non-randomized balanced controlled trials
4 cohort or case-control analytic studies
5 time series analysis
6 descriptive studies (cases and series)
7 reports of expert committees
8 opinion of respected authority lower quality more bias
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EBM emerged naturally from the availability of a
reasonable amount of research, especially RCTs, the need for
progressively better decisions and the need for standard
institutional policies. The basic idea is to merge similar samples
from several studies in the attempt to reach stronger conclusions
by analyzing the pooled samples, the meta-analysis.
Although EBM has the reputation of highest
reliability, it has some limitations12. Extrapolating to populations
different from those from which samples were taken is usually
considered a lower level of evidence13. Failure to publish
negative trials is a major problem that has been addressed by
registers of clinical trials14,15. Treatment effectiveness in the
trial set tends to be higher due the closer follow up that
enhances compliance rates16-18.
At the individual decision level, EBM seems weaker19
but there is growing evidence that it improves health care
when applied at the institutional level as guidelines20.
The reader must be aware that a lower quality report
does not mean a bad article at all. It expresses only how directly
one can apply its conclusions to daily practice. Actually,  the
trend of rejecting cases and series reports, both by editors
and by readers, means that EBM’s concept of quality has
been widely misunderstood21. In EBM, only those studies ruled
as well designed are taken into account. Thus, well designed
and well analyzed studies of any kind will be considered of
better quality than a poorly designed RCT. Cases and series
reports are still good sources of information and discoveries
that may guide future research and make the practitioner aware
of previously unknown facts21.
Evidence derived from meta-analysis must be stratified
according to its strength represented by categories of
recommendation. A sensible and widely used categorization is
the one proposed by the U.S. Preventive Services Task Force22.
Producing Evidence
The steps towards evidences are straightforward but
arduous and tricky in the details. The work starts with a
thorough review of the literature. All known sources of
references must be included. Search criteria must be wide.
This results in extensive lists but there is a smaller risk of
missing some relevant piece of information. Lists are then
scrutinized and possibly relevant articles are retrieved. All of
them are read and the ones eligible to the study by previously
defined inclusion criteria are selected for analysis23. This set
of procedures is known as systematic review.
Initial lists may include thousands of references.
Frequently more than a hundred papers need to be retrieved.
A few of them will actually be relevant according to criteria like
those in Table 1.
To avoid selection bias, the whole search and
selection work is performed by a team of not less than three
reviewers and usually all of them must agree that a given paper
meets the inclusion criteria so it is actually included in the
analysis23.
Analysis
The samples extracted from each article are then
evaluated for homogeneity. They must be similar so they can
be compared or merged. Homogenous samples are then merged
when possible and analyzed according to the questions the
study intends to answer.23   Some tools are typically used in
EBM.
Likelihood Ratios
Derived from 2x2 contingency tables, the Likelihood
Ratios (LRs) values may look strange to the reader since
they do not lie in the unit interval like probabilities do.
However, they are powerful tools for different sets. Using
Bayesian statistical approaches, one can multiply the so-
called “a priori” (or pre-test) probability by the likelihood
ratio and derive directly the probability of disease (or non-
disease),24 the so-called “a posteriori” (or post-test)
probability. Likewise, LRs can be multiplied by odds to
produce the posterior odds. Odds and probabilities can easily
be converted one to the other.
Suppose a surgeon works in a reference center for
patients that are supposed to need emergency surgeries.
This surgeon knows that about 60% of all abdominal pain
cases  will be operated on for appendicitis. He uses this
number as his “a priori” probability (0.6) or odds (3/2) and
multiplies by LR (disease/non-disease) of signs and
symptoms previously determined relevant by EBM analysis
and gets the “a posteriori” probabilities or posterior odds
of disease/non-disease. Another surgeon in an emergency
department is likely to have a smaller “a priori” probability,
say 0.2 (20%) or odds 1/4. Despite the wide difference in
the “a priori” probability in these examples it is so unlikely
that it will impact the “a posteriori” probability or odds to
the point of missing a significant proportion of diagnoses.
Actually, chaining several LRs of several signs and
symptoms as real situations demand has the reputation of
overestimating the “a posteriori” probability.24 In Surgery
this feature may be highly desirable. This kind of decision
rule has been efficient in the delivery of better health care
even in critical situations25-29.
There is a proposed fully Bayesian meta-analysis
method that besides the probability of disease provides the
strength of the evidence of each sign, symptom or test and
the average strength of evidence, called diagnosability. This
method has not been widely applied but has been shown to
be a potentially powerful tool to produce desirable decision
rules30.
Area under the ROC Curve
A tool widely used in EBM is the receiver operator
characteristic (ROC) curve. It represents the relationship
between specificity and sensitivity. The area under the ROC
curve expresses the power of a given test, sign or symptom to
differentiate disease and non-disease states. The higher the
values of sensitivity and specificity, the larger the area under
the ROC curve, consequently, the better the test. The ideal
test should produce an area equal to 1.
Another desirable product of the ROC curve is the
cut-off value, the point of the curve that is closer to the upper
left corner of the graph (Figure 1)31 and expresses the best
combination of sensitivity and specificity.
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High quality reports about tests or signs should
provide information about the areas under the ROC curves as
well as cut-off values for positive and negative tests or signs.
Number Needed to Treat
The number needed to treat (NNT) is expression of
the intervention effectiveness. It can be applied to any
treatment modality or diagnostic test. The proper way to
reason with NNT is how many patients should be treated to
have one positive response or, in the case of a test, how many
tests should be performed to produce one diagnosis32,33.
Many reports provide NNTs. From those that do not,
the reader can easily calculate them from reported
proportions33.
The ideal NNT equals 1, i.e., every treatment will
produce a positive response and every test will produce a
diagnosis. NNTs of 2 or 3 represent a quite high effectiveness
of an intervention or test. Most NNTs seen in clinical setting
with effective interventions will range between 5 and 2032,34-36.
The range from 20 to 40 may still represent clinical usefulness.33
One must be aware that different NNTs, obtained in different
clinical situations, should never be compared36.
Number Needed to Harm
The number needed to harm (NNH) describes the
number of patients we should treat to produce one more
undesirable effect comparing to the alternative treatment,37
ideally placebo.
It is intuitively apparent that the lesser the NNH, the
worse the treatment. Besides drugs side effects, NNH can be
used in cost analysis, for instance, but this kind of use deserve
more sophisticated statistical methods33.
There are no fixed limits to NNH. The risk of the clinical
use of a treatment can only be properly assessed when we
know the benefit this treatment produces in relation to the
severity of illness.
Quality and Relevance
The primary purpose of medical practice is the
delivery of good heath care. This is true for both the
administrator and the physician. Although the latest method
of research, powerful enough to produce wide and positive
institutional influence and invaluable as a source of knowledge,
EBM is not the definitive solution to questions the arise from
clinical reasoning. For the daily work of the practitioner it is
once more source of clues, as relevant as RCTs, and reports of
lower strength from the EBM stand point. The concept of
quality applies only for the EBM methods. For surgeons,
physicians, practitioners, all sources of knowledge may have
their relevance.
Final Remarks
After the first challenge, selecting good sources of
knowledge, our second hard task regarding the vast literature
is to define which acquired knowledge should change or
influence our practice. This decision is private to each
physician. It depends primarily of reader’s background
knowledge and experience. Sometimes this background is not
enough for one to learn all a report can deliver.
This is the third hard task related to reading medical
scientific reports: recognizing the need for and acquiring an
adequate background.
Reading a paper has become a highly specialized skill.
The ability to criticize and assess the relevance of any piece of
medical information, always with a moderate dose of
skepticism, is nowadays critical for any practitioner to be up
to date.
Glossary
odds: probable number of times an event is likely to
occur, expressed as the ratio of number of probable
occurrences to the number of probable non-occurrences
(source: Business Dictionary).
unit interval: the numeric interval between zero and
one.
Bayesian: paradigm used to produce strictly
probabilistic inferences, opposed to classical statistics that is
based upon repetition of ideal experiments.
Conversion Rules and Calculations
P(d) – probability of disease
P(nd) – probability of non-disease
LR(d) – likelihood ratio of disease
LR(nd) – likelihood ratio of non-disease
O – odds
Op – posterior odds
P(d) = LR(d) * [“a priori” probability]
P(nd) = 1 – P(d)
Op = LR(d) * O
P = O / (1+O)
Examples
Take the odds 1/4 used as illustration above. The “a
priori” probability of disease is given by
P(d) = O / (1+O) = 1 / (1+4) = 0.2 (20%)
and of non-disease is given by
P(nd) = 1 – P(d) = 0.8 (80%).
After processing a hypothetical decision rule for the
diagnosis of appendicitis in patients with abdominal pain, the
Figure 1 – ROC curves of four methods designed to predict mortality
in pediatric intensive care units.31
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surgeon obtained, for a given patient, LR(d) = 4.5 and LR(nd)
= 0.125. Thus,
P(d) = 4.5 * 0.2 = 0.9 (90%) (this is the “a posteriori”
probability of disease)
P(nd) = 0.125 * 0.8 = 1 – P(d) = 0.1 (10%) (this is the “a
posteriori” probability of non-disease)
Besides,
Op1 = 4.5 * 1 = 4.5 (posterior odds of disease)
Op2 = 0.125 * 4 = 0.5 (posterior odds of non-disease)
Op = 4.5/0.5 = 9/1 (posterior odds)
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ABSTRACT
Evidence-based Medicine (EBM) has become a major source of medical knowledge. It handles complexities of virtually every
method or technique used in research. The  knowledge on how the EBM researcher retrieves information, judges for
relevance and analyzes derived data is invaluable for the skillful reader of medical scientific reports (Rev. Col. Bras. Cir.
2008; 35(2): 141-145).
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